Wire · opportunities
Brepocitinib Controls Skin Disease in Dermatomyositis
◆ Sectors
Drug DiscoveryMedtech
◆ Source
◆ Verified
Fusion42 · 27 August 2026 · Fusion42 review
Brepocitinib, an oral TYK2 and JAK1 inhibitor, demonstrated rapid and sustained improvement in skin disease activity and quality of life over 52 weeks in adults with dermatomyositis in a phase 3 trial.
This Wire brief sits within Fusion42's coverage of Drug Discovery and Medtech.
◆ ◆ The Wire takeaway
You have a chance to offer patients with dermatomyositis a targeted oral therapy that controls skin symptoms faster and more effectively than existing treatments. This opens new routes for drug positioning in autoimmune skin conditions where rapid symptom relief is critical.
◆ Coverage
1 source · 27 Aug 2026
◆ Related on Wire
◆ Topics
Drug DiscoveryMedtechdermatomyositistyk2-jak1-inhibitorclinical-trialskin-diseasedrug-efficacy